Evidence map›Paper›PMID 32104590›Full record

ArticleTranslational neuroscience2020

Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with Schizophrenia: A Pilot Study.

Justine Chapuis, Francesca Siu-Paredes, Claire Pavageau, Gilles Amador, Nathalie Rude, Frédéric Denis

Open access · goldAbstract read
In one paragraph

Article in Translational neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Medication impact on oral health in schizophrenia.Medicina oral, patologia oral y cirugia bucal · 2024
    Article
  5. Article
  6. Article
  7. Psychometric Properties of the Schizophrenia Oral Health Profile: Preliminary Results.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Justine ChapuisUniversity Hospital of Tours ,Odontology Department, 37170 Chambray-lès-Tours, France.
Francesca Siu-ParedesEA 481 Integrative Neurosciences and Clinical. University Hospital of Besançon, 25000 Besançon, France.
Claire PavageauUniversity Hospital of Tours. Service d'odontologie du CHU de Tours, 37170 Chambray-lès-Tours, France.
Gilles AmadorUniversité de Nantes, Faculté d'Odontologie de Nantes, 44000 Nantes, France.
Nathalie RudeEA 481 Integrative Neurosciences and Clinical. University Hospital of Besançon, 25000 Besançon, France.
Frédéric DenisUniversity Hospital of Tours ,Odontology Department, 37170 Chambray-lès-Tours, France.
Centre Hospitalier Universitaire de Tours · FRNantes Université · FRUniversité de Reims Champagne-Ardenne · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to explore, in a sample population of people with schizophrenia (PWS), the role of the anticholinergic burden on the perception of oral health-related quality of life (OHrQoL) in France.

methodsA pilot study was performed between March 2014 and January 2016. PWS were recruited from a population in Côte d'Or department in France. Dental status was investigated using the Decayed, Missing, or Filled Teeth (DMFT) index, the Xerostomia Index (XI), and the Global Oral Health Assessment Index (GOHAI) for OHrQoL. The anticholinergic impregnation score was recorded using the anticholinergic impregnation scale (AIS).

resultsA sample of 62 people was selected. The DMFT score was 16.5± 8.7, the XI score was 22.9±7.8, the GOHAI score was 43.0±8.8, and the AIS score was 3.1±2.8. In total, 169 drugs were prescribed to the people of our sample, and 114 different anticholinergic drugs were observed. The most frequently used anticholinergic drugs (51.40%), in the study had a low antimuscarinic potency (1 point according to AIS scale). The multiple linear regression model showed that the OHrQoL scores were significantly lower when the DMFT scores, XI score, and anticholinergic scores were high.

conclusionsThis pilot study highlighted the potential role of the anticholinergic burden on the OHrQoL of PWS. A study with a validated specific scale for the OHrQoL and a standard anticholinergic burden scale should be conducted to clarify the role of anticholinergic drugs on the OHrQoL for PWS.

Indexed as

anticholinergic drugsoral diseaseoral healthoral health related quality of lifeschizophrenia

Identifiers

PMID32104590
PMCPMC7029653
OpenAlexW3005757951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.